CD274 and colorectal carcinoma: To overcome some of these shortcomings, Emami et al. (2019) designed doxorubicin (DOX)-conjugated and anti-PD-L1 targeting gold nanoparticles (PD-L1-AuNPs-DOX) for colorectal cancer (CRC).